(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 19.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.44%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Nurix Therapeutics's revenue in 2026 is $71,779,000.On average, 19 Wall Street analysts forecast NRIX's revenue for 2026 to be $5,517,940,993, with the lowest NRIX revenue forecast at $4,088,976,063, and the highest NRIX revenue forecast at $8,822,066,936. On average, 18 Wall Street analysts forecast NRIX's revenue for 2027 to be $8,560,863,852, with the lowest NRIX revenue forecast at $4,293,719,573, and the highest NRIX revenue forecast at $23,582,729,713.
In 2028, NRIX is forecast to generate $13,173,900,576 in revenue, with the lowest revenue forecast at $871,504,192 and the highest revenue forecast at $37,550,786,933.